Evidence map›Paper›PMID 42330040›Full record

ArticlePLoS pathogens2026

Maturation of HIV-1 neutralizing antibodies in a germinal center conditional expression mouse model.

Ming Tian, Jillian Davis, Hwei-Ling Cheng, Lily M Thompson, Marie-Elen Tuchel, Aimee Chapdelaine Williams, Audrey Yin, Bailey Wilder, Ivy DiBiase, Michael S Seaman and 1 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ming TianProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-4350-3380
Jillian DavisProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Hwei-Ling ChengProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Lily M ThompsonProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Marie-Elen TuchelProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Aimee Chapdelaine WilliamsProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Audrey YinProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.
Bailey WilderCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Ivy DiBiaseCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Frederick W AltProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, HHMI, Boston, Massachusetts, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In germinal centers, activated B cells modify their antigen receptors through somatic hypermutation (SHM), followed by antigenic selection that favors expansion of high affinity B cells. The affinity maturation process is critical for development of broadly neutralizing antibodies (bnAbs) against the human immunodeficiency virus-1 (HIV-1). BnAbs have been isolated from some people living with HIV-1. Because these antibodies target conserved epitopes of the HIV-1 Envelope (Env) protein, they inhibit a broad spectrum of viruses. Eliciting bnAbs by vaccination is a top priority for HIV-1 prevention, but reproducing the lengthy maturation of bnAbs is a major challenge. The problem is typified by VRC01 class antibodies, which recognize the CD4 binding site of HIV-1 Env protein. To reach the CD4 binding site, antibodies need to navigate through adjacent glycans. Accommodating the glycans requires multiple SHMs in germinal center (GC) B cells, including infrequent events. For this reason, VRC01 vaccine development often stalls at this point. We have generated a mouse model aimed at providing a potential solution for navigating this vaccine design impediment. To this end, we made a mouse model that expresses a stalled VRC01 intermediate conditionally in GC B cells. This system has three advantages: 1) direct expression of the intermediate obviates prior immunization steps, thereby shortening the immunization scheme; 2) the conditional expression system bypasses tolerance control checkpoints that sometimes delete B cells expressing bnAbs; 3) the intermediate responds to immunization in GCs, the physiological site of affinity maturation. With this model, we established an immunization method to mature the VRC01 intermediate into heterologous neutralizing antibodies against viruses with a native glycan shield. Since high mutation load is common among bnAbs, the germinal center conditional expression system could provide a general tool for boost immunogen design to overcome roadblocks in the maturation pathway.

Indexed as

Antibodies, NeutralizingGerminal CenterHIV-1HIV AntibodiesHIV InfectionsAIDS VaccinesAnimalsAntibodies, MonoclonalB-LymphocytesBroadly Neutralizing AntibodiesHumansMiceAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesVRC01 monoclonal antibody

Identifiers

PMID42330040
PMCPMC13313368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.